NeuroVive Aims to Find Path Forward in Antiviral Development Following Discontinuation of OCB-030 Preclinical Program by Arbutus
Lund, Sweden, 28 October 2015– NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that they will seek to find a suitable path forward to continue the development of the compound, which is currently out-licenced to Arbutus Biopharma.Arbutus Biopharma, formerly OnCore Biopharma, has decided to discontinue development of OCB-030 (NVP018) so the company can focus its resources on other agents that directly target HBV. NeuroVive believes that the compound still has future potential based on the extensive, independent evidence that supports its application in